Status:
COMPLETED
Transcutaneous Submandibular Gland Biopsy: Feasibility of Repeat Biopsy as a Progression Marker for Parkinson's Disease
Lead Sponsor:
Mayo Clinic
Conditions:
Parkinson Disease
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
The purpose of this study is to perform biopsies of one of the glands that make saliva. The biopsied tissue will then be analyzed to see if it has changes that occur in Parkinson's disease. This study...
Detailed Description
Tissue biopsies documenting the presence and density of Lewy type synucleinopathy (LTS) in living patients with probable Parkinsons disease (PD) would be extremely valuable as a diagnostic test, as a ...
Eligibility Criteria
Inclusion
- Inclusion criteria
- PD patients ages up to age 85.
- Previous participation in a SMG biopsy study at Mayo Clinic Arizona with a positive biopsy being reported
- Exclusion criteria
- Evidence for dementia that would preclude the patient from signing informed consent
- History of bleeding diathesis or hematologic disorders
- Medically unable to undergo a core needle biopsy of the submandibular gland
- Prior treatment of the submandibular gland with botulinum toxin injections.
- History of past or current acute infection or abscess of the submandibular gland.
- History of past or current neoplastic process within the submandibular gland.
- History of peripheral neuropathy.
Exclusion
Key Trial Info
Start Date :
November 21 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2018
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT03359226
Start Date
November 21 2017
End Date
May 31 2018
Last Update
November 6 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259